Nurse Practitioners Now Control More Diabetes Drug Spending Than Endocrinologists
$3.7 billion versus $3.1 billion. Those two numbers, both representing GLP-1 drug spending in 2023, belong to nurse practitioners and endocrinologists respectively. Nurse practitioners spent more.
That gap, $634 million, marks a structural shift in who controls the most expensive drug category in Medicare history. Nurse practitioners accounted for 19.51% of total GLP-1 drug spending in 2023, compared to 16.18% for endocrinologists. Specialists who spent careers training to manage complex diabetes are no longer the dominant prescribers of the drugs that define the field.
Primary Care Has Already Won the GLP-1 Market
The full picture is starker than the NP-versus-endocrinologist comparison suggests. Family practice leads all specialties at $5.35 billion, or 28.02% of total GLP-1 costs. Internal medicine follows at $4.77 billion, representing exactly 25%. Add nurse practitioners at 19.51% and physician assistants at 6.66%, and the non-specialist prescribers collectively account for well over half of all GLP-1 spending.
| Specialty | Total GLP-1 Cost | Share of Total |
|---|---|---|
| Family Practice | $5,348,449,312 | 28.02% |
| Internal Medicine | $4,773,525,217 | 25.00% |
| Nurse Practitioners | $3,723,719,485 | 19.51% |
| Endocrinology | $3,089,128,682 | 16.18% |
| Physician Assistants | $1,270,751,830 | 6.66% |
This distribution reflects the scale of GLP-1 adoption beyond traditional diabetes management. When a drug class reaches 380,929 Medicare beneficiaries through nurse practitioners alone, it has moved well past the specialist referral pipeline. For patients in areas with limited access to endocrinologists, that access point matters enormously.
Volume Explains the Gap, Not Prescribing Intensity
Nurse practitioners filed 2,810,795 total GLP-1 claims in 2023. Endocrinologists filed 2,003,908. That 40% volume advantage drives the spending differential, not higher-cost prescribing. Endocrinologists actually had the highest cost per claim of any major specialty at $1,541.55, compared to $1,324.79 for nurse practitioners.
The per-claim gap is a $216.76 difference, and it runs in the opposite direction from what the total spending numbers imply. Endocrinologists are writing fewer prescriptions but at higher per-claim costs. Nurse practitioners are writing far more prescriptions at lower per-claim costs.
The beneficiary counts add another dimension. Endocrinologists served 437,716 beneficiaries despite generating less total spending than nurse practitioners, who covered 380,929 beneficiaries. Endocrinologists are reaching more patients per dollar of spending, which could reflect patient complexity, formulary choices, or prescribing patterns toward higher-cost formulations. The data doesn't resolve which.
What the data does confirm: the cost-per-claim differential means that if endocrinologist prescribing patterns were applied to nurse practitioner claim volumes, total GLP-1 spending would be substantially higher. The expansion of prescribing authority to non-specialist providers has, in this drug category, produced lower per-claim costs at dramatically higher volume.
The Specialist's Shrinking Share of a Growing Market
Endocrinologists at 16.18% of GLP-1 spending are not a small player, but they are a minority one in a market they might reasonably have expected to anchor. The drugs at the center of this spending, semaglutide and its GLP-1 class peers, are the most significant pharmacological development in diabetes and obesity treatment in decades. Endocrinologists trained specifically for this patient population.
The 6.66% share held by physician assistants alone, at $1.27 billion, is not trivial. Combined with nurse practitioners, advanced practice providers account for more than a quarter of all GLP-1 spending in Medicare. That share will likely grow as prescribing authority expands and GLP-1 indications broaden beyond diabetes into cardiovascular disease and obesity.
For Medicare's actuaries, the relevant question isn't which specialty is prescribing. It's whether the $216.76 per-claim cost difference between endocrinologists and nurse practitioners persists as volume scales, and what that means for total program costs when GLP-1 utilization continues to grow.
Ask a follow-up
Run one of these against the same data. The question is filled in for you.
Explore the data yourself
Run your own queries against 240M+ rows of federal health data using natural language — powered by AI.
Start analyzing